In the latest move in the ongoing feud over their cholesterol-fighting monoclonal antibodies, Regeneron has filed a new antitrust suit against Amgen, accusing the drugmaker of carrying out an “unlawful, anticompetitive bundling scheme” to harm the market for Regeneron’s Praluent (alirocumab) in order to increase sales of Amgen’s competitor product, Repatha (evolocumab).
Source: Drug Industry Daily